OctaFX announces visual rebranding, adopts space-inspired design system

KUALA LUMPUR, Jul 26, 2022 – (ACN Newswire) – 11 years of providing brokerage services marks an important milestone for OctaFX. For the first time, the broker decided to hold a visual rebranding.

Over more than a decade, OctaFX has managed to accomplish numerous achievements. Today, clients from over 150 countries have opened more than 12 million trading accounts with the broker. To become even closer to its clients, OctaFX decided to adopt a fresh new look: with refined colours, space-inspired elements, and a new logo.

The concept

The main concept behind the rebranding reflects the broker's mission: OctaFX exists to ensure everyone can achieve their investment goals.

"We picture goals as stars in the broad universe of finance. Each one represents a unique combination of needs and desires of a particular person. The journey towards the investment goal isn't always easy – there are many obstacles on the way. To overcome them, traders need an optimal set of both analytical and financial instruments, as well as a reliable partner. We are here to provide them with everything necessary to make effective trading decisions and achieve their investment goals. All the elements of our new design system convey this message in a simple, yet illustrative way," the OctaFX press office commented.

The logo

The two orbits forming OctaFX's new logo reflect the all-encompassing support it provides for traders on the journey towards their goals. The orbits cross each other to create the word 'fx' that highlights an important part of the company name.

The elements

The elements constituting the new visual identity are all built around centre-oriented forces and objects, such as orbits and rays, reflecting the broker's continued focus on the investment goals of its clients.

The colours

The colour palette of deep blues and intense oranges gives vibrancy to the new brand design, emphasising the confidence, dynamism, and readiness to change.

The transformation

The financial world is changing rapidly. New challenges emerge every day, and OctaFX is ready to evolve and transform in response, all to meet and exceed the expectations of its clients. The new branding was created to express that.

About OctaFX

OctaFX is a global broker providing online trading services worldwide since 2011. It offers everything one needs to reach their investment goals, providing top-notch conditions utilised already by clients from over 150 countries worldwide. The company is involved in a comprehensive network of charity and humanitarian initiatives, including improvement of educational infrastructure, short-notice relief projects, supporting local communities and small to medium enterprises. On a side note, OctaFX has also won more than 45 awards since its foundation, including the 2021 'Best Forex Broker Asia' award from Global Banking & Finance Review and 2021 'Best ECN Broker' award by World Finance. www.octafx.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully

HONG KONG, Jul 21, 2022 – (ACN Newswire) – On July 21st, 2022, Lunit, a leading global AI-based cancer solutions provider invested by Legend Capital, was successfully listed on the KOSDAQ market.

Founded in 2013, Lunit successfully established itself as the world's top-notch artificial intelligence technology solution provider, mainly focusing on developing medical software to assist physicians in the realm of tumor diagnosis and treatment. Lunit's flagship products are Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT is an AI-powered image screening solution, that detects and classifies chest abnormalities and breast cancer. Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients.

Legend Capital led Lunit's series B investment round in June 2018 and continued to support Lunit's global business expansion via three additional follow-on investments in 2019 and 2021. For the past 4 years, Lunit not only has produced world-leading AI medical solutions but also gained its commercial value achieving rapid topline growth. Lunit's annual revenue grew by over 460% in 2021 since its initial product commercialization in 2019. As of now, Lunit's image diagnostic products have been certified by 42 countries/regions, including FDA, CE, and KFDA. The company will keep expanding into the global market through cooperation with international giants like GE Healthcare, Fujifilm, and Philips, etc. Legend Capital will continue to assist Lunit in finding untapped business opportunities in China by building up branding and introducing rich portfolio resources for cooperation.

Brandon Suh, CEO of Lunit, said: "Lunit's target market for cancer detection and diagnosis is worth 110 billion US dollars (of which the United States accounts for ~USD 45bn and the rest USD 65bn). Lunit's AI medical image analysis technology has significant advantages over traditional technology, and our accurate and efficient solutions have been appreciated by global medical institutions. Lunit's ongoing global expansion can be attributed to the support from our existing partners, Legend Capital has been one of Lunit's key partners in helping us grow our China business by introducing reliable local partners. Legend Capital has been and will continue to be Lunit's strategic global partner going forward."

"We like to invest in companies that have a global vision, world-leading technology, and global expansion capabilities. We were very impressed with Lunit's ambition to go global at our initial investment," said Joon-Sung Park, Managing Director of Legend Capital. "With the world's top-notch AI medical imaging technology, Lunit INSIGHT can significantly improve abnormalities detection and early-diagnosis rate, remarkably enhancing the efficiency of cancer diagnosis and treatment. Lunit has built a professional team with technology experts and medical professionals. The six co-founders are all graduates of the Korea Advanced Institute of Science and Technology (KAIST), the nation's first public, research-oriented science and engineering institution. With a commitment to empowering the medical industry by AI technology, Lunit has also hired 12 full-time doctors with an in-depth understanding of medical service. It has provided AI healthcare services to approximately 600 medical institutions in over 40 countries, and has signed an exclusive business contract with Guardant Health, the world's largest liquid biopsy diagnostic company, to collaborate on cancer drug development."

At present, "Lunit INSIGHT CXR Triage" and "Lunit INSIGHT MMG" have been certified by the U.S. Food and Drug Administration (FDA) by the end of 2021, and Lunit will continue to expand the global market by obtaining Medical Device Single Audit Program (MDSAP) certification in the US, Canada, Japan, Australia and Brazil, etc. Legend Capital has invested heavily in companies that integrate technology and the medical industry and has kept betting on AI medical sectors. In addition to Lunit, Legend Capital has also invested in AI medical companies such as Xbiome, an AI microbiome drug development company; StoneWise, an AI drug R&D platform; Deepwise, an AI medical imaging company; BioMap, a biocomputing platform; Deep Informatics ++, an AI medical pathology diagnosis company; and Unimed, an AI brain diagnosis and treatment platform.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

AppsFlyer launches comprehensive guide on gaming apps in collaboration with Facebook Gaming

SINGAPORE, Jul 19, 2022 – (ACN Newswire) – AppsFlyer and Facebook Gaming have launched an exclusive playbook for gaming app marketers. Introducing Gaming Apps: Strive and thrive with AppsFlyer and Facebook Gaming on iOS 14+, this playbook will set clear pathways and set gaming app marketers up for success.

In today's privacy-first era, gaming app marketers are constantly navigating the evolving landscape with updates to performance marketing strategy, while planning to stay ahead of the curve. Particularly to tackle the changes for users of iOS devices, advertisers have had to make several changes to adapt to new iOS 14+ policies.

Showcasing the best practices and solutions for gaming app marketers and advertisers, the AppsFlyer and Facebook Gaming playbook provides insights to tackle the challenges of iOS 14+ from 3 different perspectives: Optimizing the App Tracking Transparency (ATT) prompt, maximizing SKAdNetwork (SKAN) measurement, and unifying data streams.

This playbook also contains recommendations from Facebook Gaming derived from a comprehensive directory on SKAN configuration, campaign setup, and campaign management, to help marketers achieve and scale their gaming app marketing success.

To learn more about the playbook and gain pro tips to utilizing tools available for maximized marketing and advertising performance, visit: Gaming apps: Strive and thrive with AppsFlyer and Facebook Gaming on iOS 14+ https://content.appsflyer.com/af-and-fb-gaming-ios-playbook/

About AppsFlyer

AppsFlyer, the global attribution leader, helps brands make good choices for their business and their customers through innovative, privacy-preserving measurement, analytics, fraud protection, and engagement technologies. Built on the idea that brands can increase customer privacy while providing exceptional experiences, AppsFlyer empowers thousands of creators and 9.000+ technology partners to create better, more meaningful customer relationships. To learn more, visit www.appsflyer.com

Media Contacts
PRecious Communications on behalf of AppsFlyer
appsflyer@preciouscomms.com

Media Contacts for AppsFlyer South East Asia
Annisa Tiara
annisa.tiara@appsflyer.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Society Pass (SoPa) Marks First Foray into Thailand by Acquiring Bangkok-Headquartered Thoughtful Media Group, Southeast Asia’s Leading Digital Video Multi-Platform Network and Social Commerce Platform

SINGAPORE, Jul 11, 2022 – (ACN Newswire) – Society Pass Incorporated ("SoPa" or "Society Pass") (Nasdaq: SOPA), Southeast Asia's leading data-driven loyalty platform, today announces the acquisition of Thoughtful Media Group ("Thoughtful Media"), a social commerce-focused, premium digital video MPN headquartered in Thailand with an operating presence in the US, Vietnam, and Philippines. The acquisition of Thoughtful Media marks SoPa's first foray into Thailand and adds to SoPa's growing ecosystem of technology-enabled companies located in the SEA countries of Vietnam, Philippines, Singapore and Thailand.

Originally founded in 2010, Thoughtful Media today creates and distributes digital advertising campaigns across its MPN in both SEA and the US. With its intimate knowledge of local markets, digital marketing technology tools and social commerce business focus, advertisers leverage Thoughtful Media's wide influencer network throughout SEA to market and sell advertising inventory exclusively with specific placement and effect. As a result, Thoughtful Media's content creator partners earn a larger share of advertising revenues from international consumer brands. And according to Accenture, the social commerce market is poised to grow to US$1.2 trillion by 2025 at a CAGR of 26%.

Thoughtful Media recorded revenues of US$5.8 million in 2021. Since its founding, Thoughtful Media's data-rich MPN has uploaded over 675,000 videos with over 80 billion video views. The current network of 263 YouTube channels has onboarded over 85 million subscribers with an average monthly viewership of over 600 million views.

Thoughtful Media's social commerce platform amplifies the reach and engagement of SoPa's e-commerce ecosystem and retail partners. The growing ubiquity of social media influencers on shaping purchase decisions has driven increasingly greater numbers of brands to shift advertising budgets to this dynamic outlet. SoPa aims to increase customer engagement whilst also focusing on the quality of relationships through a campaign-based approach enabled by this synergistic acquisition.

Thoughtful Media's digital advertising tools and expertise bolsters Society Points, SoPa's paradigm shifting loyalty platform. Through data-driven marketing campaigns, advertisers of all types utilise Society Points' proprietary 1st party data to improve the targeting, efficacy, and efficiency of their digital marketing spend. SoPa's product offering uniquely positions Thoughtful Media as a leading SEA retail marketing and advertising hub for international and regional consumer brands.

Dennis Nguyen, Society Pass Founder, Chairman, and Chief Executive Officer comments, "We are thrilled to have Thoughtful Media join the ever-expanding SoPa ecosystem. Thoughtful Media's social commerce-focused business model perfectly complements our future growth strategy for Society Pass as we drive consumer eyeballs and generate revenues for riveting consumer brands throughout Southeast Asia. In addition, Society Pass is excited to complete our first Thailand acquisition and look forward to launching our SoPa loyalty platform to the 65 million consumers in Thailand".

Dan Thorman, Thoughtful Media Chief Executive Officer explains, "Thoughtful Media is led by an experienced management team in SEA and the US. We provide media owners with content creation and technology services that build and monetise their brands' audience on numerous social platforms. With years of on-the-ground experience and industry expertise in developing influencer talent, producing social media content, coordinating advertising campaigns, aggregating influencer data, and onboarding millions of viewers onto our data-rich MPN, we track hundreds of millions of authenticated global video views a month across key social media platforms. Partnering with Society Pass allows Thoughtful Media to unlock strategic opportunities with influencers and advertisers as well as design cross-marketing synergies for companies in the SoPa ecosystem. In doing so, we expect to drive tremendous revenue growth in 2022 and beyond".

About Society Pass

As a loyalty and data marketing ecosystem in Singapore, Vietnam, Philippines, and Thailand and with offices located in Singapore, Hanoi, Ho Chi Minh City, Manila, and Bangkok, SoPa is an acquisition-focused e-commerce holding company operating 7 interconnected verticals (loyalty, merchant software, lifestyle, F&B, telecoms, digital media, and travel) seamlessly connecting millions of consumers and thousands of merchants across multiple product and service categories in SEA.

Society Pass business model focuses on analysing user data through its Society Pass loyalty platform and circulation of its universal loyalty points or Society Points. Since its inception, SoPa has amassed over 1.6 million registered consumers and over 5,500 registered merchants/brands on its platform. It has invested 2+ years building proprietary IT architecture with cutting edge components to effectively scale and support its consumers, merchants, and acquisitions.

Society Pass provides merchants with #HOTTAB Biz and #HOTTAB POS – a Vietnam-based POS, CRM and analytics technology solutions provider for small and medium-sized enterprises. In addition, SoPa operates Leflair.com, Vietnam's leading lifestyle e-commerce platform, Pushkart.ph, a popular grocery delivery company in Philippines, Handycart.vn, a leading online restaurant delivery service based in Vietnam, and Gorilla Networks, a Singapore-based, web3-enabled mobile blockchain network operator. For more information, please check out: http://thesocietypass.com/.

Media Contacts:
PRecious Communications
sopa@preciouscomms.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB

HONG KONG, Jul 7, 2022 – (ACN Newswire) – Jiangsu Huili Biotechnology Co., Ltd ("Huili Bio"), a next-generation synthetic biology enzyme computational design platform, recently announced the completion of its Series A financing round with hundreds of million RMB. This financing round was co-led by Legend Capital and the fresh capital will be used to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines and the expansion of the talent team.

Founded in 2018, Huili Bio is dedicated to the computational design of enzyme components at the core of synthetic biological reactions. With cutting-edge achievements, Huili Bio is one of the few bio-manufacturing companies with comprehensive capabilities in core technology, mass production on a large scale and closed-loop commercialization. It provides solutions in multiple fields such as pharmaceutical intermediates, animal protection and food. In addition to an R&D center in Tianjin, Huili Bio has also established a production base in Taizhou City, Jiangsu Province, which is under the expansion of flexible production line.

Huili Bio's enzyme computational design platform is the first computational platform in China to realize the full-scenario design of enzymes. This platform enables the company to transform products in the pharmaceutical field, so as to achieve high efficiency from laboratory development, industrial production to commercialization, reducing costs by nearly 30% and increasing yields by almost 70% compared to traditional chemical methods, and also helps Huili Bio deploy more than 10 innovative products in various fields.

Commenting on the financing, Henry JI, Executive Director of Legend Capital, said: "The synthetic biomaterials market is vast and an important area in the green and low-carbon direction. As the core component of synthetic biology, the design and transformation of enzymes will benefit more traditional biotechnology industries with low-cost and sustainable green production methods. Legend Capital has long focused on investment in the 'IT+' industry, and Huili Bio is a model of combining information technology and biotechnology (IT+BT). With a background in combining industry and research, Huili Bio is a company with differentiated product selection and multi-pipeline extension capabilities. The company has mastered the industry's leading enzyme computing design technology and has rapidly achieved the scale production of high-value-added products such as pharmaceutical intermediates through the layout of the whole industry chain and has been fully recognized by the industry's head customers. Legend Capital is glad to join hands with Huili Biotech to contribute to China's biological 'intelligence'."

As an intersection of information science, life science and material science, synthetic biology and bio-based materials have been the focus of Legend Capital's carbon-neutral technology investments. Under the background of carbon peaking and carbon neutrality, Legend Capital's investments focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others. Legend Capital has made investments in the field of synthetic biology by investing in outstanding companies such as Huili Bio, Zhongke Guosheng, and Tidetron Bio.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, South Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Elite Partners Acquires Distribution Facility in UK

LONDON, Jul 6, 2022 – (ACN Newswire) – Elite Partners Capital ("EPC") has completed another acquisition of a distribution facility in the UK for over GBP 30M.

The asset is located within Wrexham Industrial Estate, a premier industrial location and one of the largest industrial estates in the UK, well placed to serve both Wales and England. The estate extends to over 550 hectares and is home to over 340 businesses creating employment for over 10,000 people. The distribution facility, consisting of two detached industrial warehouse facilities, provides in total 723,114 sqft of built up space on a 45.9 acres land. It is fully let to one of the UK's largest shop-at-home retailers Shop Direct Home Shopping (a subsidiary of The Very Group – a multi-brand online retailer and financial services provider in the UK and Ireland).

This represents the first UK acquisition for the second series of EPC's Logistic Funds. Riding on its strong track record and the deep network the manager has built over the years, Elite Logistics Fund II continues to focus on building a portfolio of high-quality logistics warehouse or infrastructure across Europe and the UK.

The acquisition in Wrexham, according to Mr. Victor Song, CEO of Elite Partners Capital, is part of the firm's bigger plan to amass an institutional-scale portfolio of prime logistics assets across Europe and the UK. He added, "We believe that this asset is particularly well-placed to benefit from the highly dynamic logistics market in the UK where the demand for logistics warehouses remains strong and resilient".

The UK Industrial & Logistics sector has seen an outperformance due to the e-Commerce boom over the years, which was further accelerated by the Covid-19 pandemic.

For this transaction, Colliers acted for Elite Partners Capital and B8 Real Estate acted for the vendor.

About Elite Partners Capital

Incorporated in 2017, Elite Partners Capital is a Singapore-based licensed fund manager. The Elite Logistics Fund series has a Pan-European strategy focusing on prime logistics assets in the high-growth and defensive sectors.

Media Contact:
enquiries@elitepartnerscapital.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Panthera Growth to Raise US$250 Million Second Fund to Back Tech Companies

Singapore, Jun 28, 2022 – (ACN Newswire) – Panthera Growth Partners (PGP), a Singapore-based tech-focused growth investment firm, today announced the first close of its second Fund, having secured commitments for more than half of the target raise. The fund's target has been set at USD 250 million, and is expected to be reached by end of this fiscal year. The fund will offer up to 100% of fund commitments in co-investment opportunities.

Shilpa Kulkarni, Founder and Managing Partner, Panthera Growth Fund

The Fund's investment objective is to partner with next generation consumption and enterprise services businesses with vast growth potential. The Fund's capital will be invested in companies that have achieved product market fit and are seeking to accelerate market growth. The Fund will deploy approx. USD20 million on average in 10-12 individual portfolio companies across India and Southeast Asia.

Backed by institutional investors from India, EU and USA, Fund II will seek to back entrepreneurs who typically employ market transformational ideas propelled by technology. Fund II has been formed to build upon the investment track record and philosophy of the firm by focusing upon investments in growth stage technology-enabled companies that are, or are poised to become, leaders in their respective markets.

Panthera was founded in 2021 and its Fund I, which raised $84 M from global institutional investors, is largely deployed across sector leading companies such as BigBasket, Pepperfry, Zivame, OfBusiness, etc.

Shilpa Kulkarni, Founder and Managing Partner, Panthera Growth Fund, said, "We are a growth equity investor focused on revenue-generating enterprises that are building scalable businesses having achieved product-market-fit. At Panthera, we believe that operating thought partners are as just as important as capital at this growth stage. With our teams' experience of investing and operating companies in the startup ecosystem since more than two decades, we look to support entrepreneurs and management teams as they embark on an ambitious growth journey."

About Panthera Growth Partners

Panthera Growth Partners is a sector specialist investment firm investing exclusively in cutting edge technology leveraged businesses. We are differentiated by our sector specialization, deep network of operational resources and industry relationships, systematic value creation process, and strong execution capability.

For more information, visit www.pantheragp.com

Media contacts:
Mumbai: Snigdha Nair – Snigdha.nair@adfactorspr.com
Singapore: Namrata Sharma – namrata.sharma@adfactorspr.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Perseverance Asset Management: long bias and fundamental bottom-up strategy

HONG KONG, Jun 28, 2022 – (ACN Newswire) – China's hedge fund market has been building and has seen a 70% increase in total assets over the past two years to over 6 trillion RMB (US$944 billion) at the end of 2021. Equity hedge fund manager Perseverance Asset Management is taking advantage of this surge by funneling international institutional capital into China's securities market.

Perseverance's achievement has been recognised by Asia Asset Management (AAM) in its Best of the Best 2022 award for Best Domestic Private Fund Manager (China). The company's Chief Investment Officer Deng Xiaofeng was awarded the title of CIO of the Year for China.

According to Daisy Liang, head of global business development at Perseverance, global asset owners have been increasingly committed to hedge fund assets invested in China over the past five years, due mainly to the market's robust fundamentals.

"Foreign investors have a firm belief that there are a group of high-quality Chinese companies with innovative, hard-working entrepreneurs," Liang says in an interview with AAM.

Moreover, China's Securities Regulatory Commission has been taking steps to ease restrictions on margin trading and short selling on more stocks in recent years as part of its efforts to propel the domestic capital market.

Also, regulatory loosening has provided overseas investors with more comfort despite China's capital market having been through some "eventful" years, facing issues such as stock market volatility, US-China trade disputes, and the coronavirus pandemic.

Long-bias strategies

Despite the regulatory easing on short selling, Liang observes that overseas institutional investors are still generally more long-oriented in going about investing in Chinese equity assets, seeking to capture both market beta and alpha.

Perseverance primarily offers long-bias and long-only equity hedge fund solutions with a fundamental research-driven bottom-up approach. Liang says the company's solutions align with its core allocation in global asset owners' global equity portfolios, in some cases alternative portfolios.

The asset owners generally take various factors, including the sustainability of investment performance, alpha generation capability, investment philosophy, the portfolio managers' incentive alignment, and research team structure and process into account over the course of selecting hedge fund managers who invest in China.

Investment managers need to tick the boxes both in terms of investment due diligence and operational due diligence to be selected by large global institutional investors, Liang mentioned.

Perseverance's global business has developed rapidly, with some prominent international institutional investors such as pension funds and sovereign wealth funds have become its customers, boosted by investors' preference for long-oriented and fundamental equity strategies and highly selective criteria and rigorous due diligence process on managers' investment and operational capabilities.

"Long-only strategies are among the mainstream choices for overseas investors," Liang says. "They prefer to go for fundamental strategic investment styles as the approaches are similar to how they invest in global markets."

Importantly, the company's funds are overseen by a mix of portfolio managers with different investment styles, among them deep value, contrarian, and growth-oriented. Liang notes this multi-manager model meets different demands from different clients.

In terms of strategy preference, generally speaking, sovereign wealth funds and pension funds favour long-only strategies, while family offices and endowment funds generally prefer long-bias investment choices.

On investment trends, Liang says some institutional clients have rebalanced their allocation to top-up investment in China since the market sell-off in July 2021.

The market adjustment prompted them to replenish their position as the value of their China allocation dropped below the targeted level. Overall, investors are committed to the long-term and rarely adjust their core portfolio allocation, she says.

(Source: Asia Asset Management)

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Legend Capital Increases Carbon Neutrality Investments: Portfolio Company Talent New Energy Completes A++ Financing Round with Several Hundred Million RMB

HONG KONG, Jun 16, 2022 – (ACN Newswire) – Legend Capital's portfolio company Talent New Energy, a new Chinese powerhouse in the solid-state battery industry, recently announced the completion of its Series A++ financing round with several hundred million RMB. Legend Capital initially invested in Talent New Energy by joining the Pre-A financing round and continued to support the company's development by following up this Series A++ financing round.

With the improved battery technology and continuous high oil prices, the penetration rate of new energy vehicles is rising. The penetration rate of new energy vehicles in China reached 25.3% in April, and according to the industry forecasts, it will increase to 35% by the end of the year. Under the global background of carbon peaking and carbon neutrality, the wind power, photovoltaic and energy storage industry are also ushering in a golden era, gradually replacing the traditional fossil energy. With the technical advantages of high safety and high specific energy, it is widely believed in the industry that solid-state batteries will become the next trillion-level super track and the ultimate solution for battery technology.

Technology innovation is the core path to support the realization of carbon neutrality. With the acceleration of vehicle electrification, applications such as energy storage have opened up a new trillion-level market. Legend Capital actively explores suitable investment opportunities in more advanced lithium battery technologies. As a brand-new technology solution, new energy solid-state batteries have been deeply explored by many giants and startups in China and around the world. With nearly 20 years of international and domestic solid-state battery R&D technology accumulation, the Talent New Energy team has determined the oxide technology route and the gradual development path from mixed solid-liquid to all-solid-state lithium battery since the establishment of the company in 2018.

Legend Capital stated: "under the leadership of the founder Dr. GAO Xiang, the Talent New Energy team has been conducting R&D with the goal of industrialization, not only achieving a comprehensive breakthrough in product performance but also making Talent New Energy the leading semi-solid-state battery company in the market in terms of mass production capability. After the completion of the first investment in Talent New Energy last year, Legend Capital has continued to support the company's development by investing in each subsequent round of Talent New Energy's financing, helping the company become a leader in the solid-state battery industry in various aspects such as capital and industrial resources."

It is reported that Talent New Energy's first semi-solid-state power battery production line in Chongqing will be put into production in October this year. Talent New Energy said that after this round of financing, the company would accelerate the integration of technological resources to set up an advanced energy materials research institute and a new energy technology industrialization joint R&D center in Beijing. The company is accelerating the mass production and commercialization of semi-solid-state lithium batteries and striving to launch the all-solid-state lithium-ion battery at the end of this year, providing advanced and reliable energy solutions to the new energy vehicle industry and electrochemical energy storage industry and providing "energy blocks" for the construction of new infrastructure for high-efficiency cross-space-time energy storage in the future human society.

Under the goals of carbon peaking and carbon neutrality, Legend Capital's investments focus on energy system decarbonization, vehicle electrification/intelligence and synthetic biology. Energy decarbonization includes photovoltaics, wind power, smart grids; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others.

Legend Capital has long been optimistic about the electrification, intelligence, and automation of new energy vehicles. It has invested in numerous enterprises in automation equipment, lithium batteries and material in the past 10 years, many of which were went public successfully, such as Wuxi Lead Intelligent (300450.SZ), CNGR Advanced Material (300919.SZ), Putailai New Energy (603659.SH), Hymson Laser (688559.SH), Colibri Technologies (002957.SZ). Legend Capital is also one of the early investors of CATL (300750.SZ).

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Breakthrough Cooperation of Legend Capital’s Cross-border Portfolio Companies: Innovent and Etana Jointly Announce the Approval of Bevagen by the BPOM

HONG KONG, Jun 15, 2022 – (ACN Newswire) – On June 14, two of Legend Capital's portfolio companies, Innovent Biologics, Inc. ("Innovent") and PT Etana Biotechnologies Indonesia ("Etana"), jointly announced that the Indonesian Food and Drugs Authority (BPOM) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for five indications including metastatic colorectal cancer (mCRC), metastatic triple negative breast cancer (mTNBC), advanced non-small cell lung cancer(NSCLC), ovarian cancer (OC), and cervical cancer(CC). Under the approval of the BPOM, Bevagen will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.

Dr. Michael Yu, Founder, Chairman and CEO of Innovent, said, "We are pleased that under the strategic collaboration with Etana, the approval of Bevagen in Indonesia marked a meaningful step toward bringing Innovent's innovative portfolio into the global market, benefitting patients globally. Pairing Etana's commercial expertise in the local Indonesian market with Bevagen's clinical profile, high-quality production and relative affordability, we are confident that Bevagen will launch to the market quickly and benefit many cancer patients."

Nathan Tirtana, President Director of Etana, said, "Etana appreciates the support of BPOM for approving Bevagen for cancer patients in Indonesia. With this product, we believe we can provide better access to high-quality and affordable biosimilar drug to meet the need of cancer patients in Indonesia. Our next step is to implement the technology transfer and local Bevagen production in Indonesia via collaboration with Innovent."

Legend Capital has been looking for investment and partnership opportunities in the Southeast Asian market since 2019 and ultimately invested in Etana in 2020. By leveraging the advantages of the portfolio ecosystem, Legend Capital has played an active role in promoting the strategic cooperation between Innovent and Etana.

Mr. Frank Hong, Managing Director of Legend Capital, said, "Congratulations to Innovent and Etana for the approval of the first biosimilar in Indonesia. This milestone achievement demonstrates the feasibility of expanding Chinese innovative drugs market access into the emerging markets. The emerging markets along the Belt and Road have significant demand for pharmaceutical products and unmet clinical needs, Chinese innovative therapeutics are particularly well suited to the needs of patients in developing countries given their quality and affordable prices. Legend Capital will continue to explore investment opportunities in the emerging markets and actively pioneer the path for Chinese high-end biologics' overseas expansion, facilitating the globalization of Chinese pharmaceutical companies."

Mr. Fei Qi, Executive Director of Legend Capital, said, "The cross-border investment and industrial collaboration in the Southeast Asian market possess unique challenges: from policy regulation, folk culture to healthcare system complexity. Etana has set up a competitive barrier of 'Access + Manufacturing + Commercialization' in Southeast Asia, and Legend Capital complemented Etana's key 'Business Development' ability by leveraging its healthcare portfolio ecosystem. Legend Capital has provided a series of value-add services in terms of company strategy, business cooperation and subsequent financing to Etana since its investment. Etana has approached and discussed collaboration initiatives with more than 10 Chinese biopharmaceutical companies and plans to introduce more therapeutics that Indonesia currently lacks, such as cancer monoclonal antibodies, COVID vaccines, and antiviral infection drugs. Through the joint efforts of Etana and its partners, we believe that the company will be able to provide high-quality and affordable Chinese innovative drugs to Indonesia, Southeast Asia and even the Islamic world."

Legend Capital has been firmly positioned to invest systematically in the field of innovative medicine. Adhering to the investment philosophy of "Global Vision, Chinese Insights", Legend Capital is looking for truly internationally competitive technologies and teams to solve the unmet clinical needs; many of its portfolio companies have been listed on A-share or H-share successfully, such as Kawin Technology (688687.SH), Innovent Biologics (01801.HK), Hbm (02142.HK), Recbio Technology (2179.HK). At the same time, we also made investments in segment-leading companies such as GluBio Pharmaceutical, Ribo Life Science, PegBio, Exegenesis Bio, Lynk Pharmaceuticals and Innostellar Biotherapeutics.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com